Selenium Treatment in Autoimmune Thyroiditis (AIT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00271427|
Recruitment Status : Completed
First Posted : January 2, 2006
Last Update Posted : August 23, 2006
|Condition or disease||Intervention/treatment|
|Autoimmune Thyroiditis Hashimotos Thyroiditis||Drug: L-Selenomethionine|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Selenium Treatment in Autoimmune Thyroiditis: Long Term Follow-Up With Variable Doses|
|Study Start Date :||December 2004|
|Estimated Study Completion Date :||August 2005|
- statistically important change in serum TPOAb titers.
- Observe the long term effects to 9th mo.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00271427
|Dep. of Nuc. Med., Ege University Faculty of Medicine.|
|Izmir, Turkey, 35100|
|Principal Investigator:||Omer Turker, Specialist||Dep. of Nuc. Med., Gulhane Military Academy of Medicine|
|Study Director:||Kamil Kumanlioglu, Prof.||Dep. of Nuc. Med., Ege University Faculty of Medicine.|